Summary of standard dosage versus the combination of other treatment plus low-dose tPA
| Author | Year | Racial (% black) | Sample | Age (IQR) | Baseline NIHSS (IQR) | Time window (hour) | Dosage (mg/kg) | Other | Control 0.9 mg/kg/L | Favourable outcome (%)* | sICH (%) | Mortality |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Morihara | 2016 | Japanese | 21 | 71.7 | 10 (6–16) | <4.5 | 0.6 | |||||
| Opeolu39 Adeoye | 2015 | 13 | 85 | 68 (33–86) | 11 (6–31) | 2 | 0.6 | Eptifibatide | 0.9 | 52 | 0 | 15.3 |
| Pancioli | 2013 | 13.9 | 101 | 71.6 (58.1–81.5) | 19 | <4.5 | 0.6 | Eptifibatide | 0.9 | 43.6 | 2 | 19.8 |
| Pancioli | 2008 | NA | 29 | 72.7 (67–77 | 14.0 (10–20) | <3 | 0.3 | Eptifibatide | 0.9 | 31.0 | 3 | 28.0 |
| 40 | 68.0 (52–77) | 13.5 (8–17) | <3 | 0.45 | Eptifibatide | 0.9 | 30.0 | 0 | 18.0 | |||
| IMS II | 2007 | 11.1 | 81 | 64±11.5† | 19 | <3 | 0.6 | IA thromolysis+EKOS system | NA | 33.0 | 9.9 | 16.0 |
*Favourable outcome indicates modified Rankin scale 0–1 at 3 months follow-up.
†Only mean±SD were available.
IA, intra-arterial; IMS, Interventional Management of Stroke; NA, not available; NIHSS, National Institution of Health Stroke Scale; sICH, symptomatic intracranial haemorrhage, refer to NINDS criteria; tPA, tissue plasminogen activator.